1-3 of 3
Karen Yee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff, Kevin R. Kelly, Karen Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David Bowen, Giovanni Martinelli, Mark W. Drummond, Paresh Vyas, Mark Kirschbaum, Swaminathan Padmanabhan Iyer, Vivian Ruvolo, Graciela M. Nogueras González, Xuelin Huang, Gong Chen, Bradford Graves, Steven Blotner, Peter Bridge, Lori Jukofsky, Steve Middleton, Monica Reckner, Ruediger Rueger, Jianguo Zhi, Gwen Nichols, Kensuke Kojima
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 868–876.
https://doi.org/10.1158/1078-0432.CCR-15-0481
Published: 14 February 2016
View article titled, Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Open the PDF for Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Aaron D. Schimmer, Susan O'Brien, Hagop Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis Giles, Andre Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel-Reid, Mark Berger, Jean Viallet, Gautam Borthakur
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8295–8301.
https://doi.org/10.1158/1078-0432.CCR-08-0999
Published: 15 December 2008
View article titled, A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Open the PDF for A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window